Replies to post #130048 on Biotech Values

[biomaven0]

Do you think this 3rd-line represents a large enough commercial market in regards to Exelixis's current market cap?

Yes - everyone fails the existing drugs at some point. Only difference would be that (unlike say abiraterone) you may only be treating the patients for a few months.

Peter